NCT07025512 2026-04-16
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
M.D. Anderson Cancer Center
Phase 2 Suspended
Clinical Trials
27 trialsNCT05849298 2026-04-13
PSMACare
Novartis
Phase 2 Active not recruiting
NCT06894511 2026-04-08
PSMAndARPI
Novartis
Phase 2 Active not recruiting
NCT07047118 2026-04-08
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT06632977 2026-04-07
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT05114746 2026-04-01
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting
NCT04663997 2026-03-27
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT06526299 2026-03-24
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
Phase 2 Recruiting
NCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT06216249 2026-03-10
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT06004661 2026-03-06
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Novartis
Phase 2 Recruiting
NCT04443062 2026-02-27
Bullseye
Radboud University Medical Center
Phase 2 Completed
NCT06964958 2026-02-24
LASER
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06145633 2026-01-28
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT06866938 2026-01-06
ReaLuP
Hospices Civils de Lyon
Phase 2 Recruiting
NCT06084338 2025-12-31
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
VA Office of Research and Development
Phase 2 Recruiting
NCT05766371 2025-12-30
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT06852820 2025-09-23
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT06200103 2025-09-11
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06738303 2025-08-27
CATCH-177
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT04343885 2025-07-11
UpFrontPSMA
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT06972628 2025-05-15
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Recruiting
NCT06449781 2025-02-10
PSMA-ADJUVO
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Recruiting
NCT06783348 2025-01-23
RENALUT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Not yet recruiting
NCT05150236 2023-12-15
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT03392428 2022-06-13
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03042312 2021-03-24
RESIST-PC
Endocyte
Phase 2 Terminated